Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 3:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: surfactant airway device Clear all
Completed Phase 3 Interventional Results available

Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients

NCT03058666
View directory record Official record
Conditions
Respiratory Distress Syndrome
Interventions
Aerosolized Calfactant, Solarys
Drug · Device
Lead sponsor
ONY
Industry
Eligibility
1 Hour to 24 Hours
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Mobile, Alabama • Phoenix, Arizona • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 24, 2026, 3:23 PM EDT
No Longer Available No phase listed Expanded access

Aerosolized Infasurf Treatment Protocol: Aerosolized Infasurf for Spontaneously Breathing Patients With Early RDS (AERO-03)

NCT03582930
View directory record Official record
Conditions
Neonatal Respiratory Distress
Interventions
Infasurf Aero
Combination Product
Lead sponsor
ONY
Industry
Eligibility
Up to 42 Weeks
U.S. locations
5
States / cities
Jackson, Mississippi • Buffalo, New York • Greenville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 24, 2026, 3:23 PM EDT
Recruiting Not applicable Interventional

Comparing Surfactant Administration Through Supraglottic Airway and Thin Catheter for Preterm Infants

NCT07030270
View directory record Official record
Conditions
Surfactant, Respiratory Distress Syndrome (Neonatal)
Interventions
Surfactant Administration through Laryngeal or Supraglottic Airway, Surfactant Administration through Thin Catheter
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
0 Hours to 72 Hours
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

Surfactant Positive Airway Pressure and Pulse Oximetry Trial

NCT00233324
View directory record Official record
Conditions
Infant, Newborn, Diseases, Other Preterm Infants, Infant, Small for Gestational Age, Premature Birth, Bronchopulmonary Dysplasia, Retinopathy of Prematurity
Interventions
Surfactant, Continuous Positive Airway Pressure (CPAP), Supplemental oxygen with target saturation of 85 to 89%, Supplemental oxygen with target saturation of 91 to 95%
Drug · Device
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
24 Weeks to 27 Weeks
Enrollment
1,316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact

NCT03969992
View directory record Official record
Conditions
Respiratory Distress Syndrome in Premature Infant
Interventions
AeroFact, nCPAP
Drug · Other
Lead sponsor
Aerogen Pharma Limited
Industry
Eligibility
26 Weeks to 31 Weeks
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
37
States / cities
Little Rock, Arkansas • Berkeley, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 24, 2026, 3:23 PM EDT
Terminated Not applicable Interventional

Randomized Controlled Trial of Surfactant Administration by Laryngeal Mask Airway (LMA)

NCT00599651
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Surfactant administered via Laryngeal Mask Airway (LMA), standard of care (nasal CPAP and supplemental oxygen)
Device · Other
Lead sponsor
University of Virginia
Other
Eligibility
Up to 72 Hours
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 6, 2010 · Synced Sep 24, 2026, 3:23 PM EDT
Not listed Phase 4 Interventional

OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP

NCT02140580
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Minimally invasive surfactant therapy, Continuation on CPAP
Device · Other
Lead sponsor
Menzies Institute for Medical Research
Other
Eligibility
1 Minute to 6 Hours
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
5
States / cities
New Haven, Connecticut • Honolulu, Hawaii • Evanston, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Sep 24, 2026, 3:23 PM EDT
Terminated Phase 3 Interventional

Early Surfactant to Reduce Use of Mechanical Breathing in Low Birth Weight Infants

NCT00005774
View directory record Official record
Conditions
Infant, Newborn, Respiratory Distress Syndrome, Respiratory Insufficiency
Interventions
Early surfactant, Standard practice
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 12 Hours
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Not applicable Interventional

Early Caffeine and LISA Compared to Caffeine and CPAP in Preterm Infants

NCT04209946
View directory record Official record
Conditions
Premature Lungs, Respiratory Distress Syndrome, Surfactant Deficiency Syndrome Neonatal
Interventions
Less Invasive Surfactant Administration LISA, Continuous Positive Airway Pressure CPAP
Procedure
Lead sponsor
Sharp HealthCare
Other
Eligibility
24 Weeks to 29 Weeks
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Irvine, California • Loma Linda, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 24, 2026, 3:23 PM EDT
Terminated Phase 4 Interventional Results available

Surfactant Via Endotracheal Tube vs. Laryngeal Mask Airway (LMA) in Preterm Neonates With Respiratory Distress Syndrome

NCT02164734
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Endotracheal intubation, Laryngeal mask airway, remifentanil
Device · Drug
Lead sponsor
Albany Medical College
Other
Eligibility
2 Hours to 48 Hours
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 24, 2026, 3:23 PM EDT
Terminated Phase 2 Interventional Results available

Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants

NCT00807235
View directory record Official record
Conditions
Respiratory Distress Syndrome
Interventions
Aerosolized lucinactant
Drug
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
15 Minutes to 30 Minutes
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Not applicable Interventional Results available

Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates

NCT01116921
View directory record Official record
Conditions
Respiratory Distress Syndrome
Interventions
Nasal continuous positive airway pressure (nCPAP), Laryngeal Mask Airway (LMA) to deliver surfactant, Surfactants, Pulmonary
Device · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
Up to 36 Hours
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
Loma Linda, California • San Diego, California • Maple Grove, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

Delivery Room Management Trial of Premature Infants at High Risk of Respiratory Distress Syndrome

NCT00244101
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
PS Group, NCPAP Group, ISX Group
Drug · Device
Lead sponsor
Vermont Oxford Network
Network
Eligibility
26 Weeks to 29 Weeks
Enrollment
648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Sep 24, 2026, 3:23 PM EDT
Enrolling by invitation Not applicable Interventional

Surfactant Using a Supraglottic Airway Device in Late Preterm to Early Term Infants

NCT07176117
View directory record Official record
Conditions
Respiratory Distress Syndrome (Neonatal), Surfactant
Interventions
Surfactant Administration Through Laryngeal or Supraglottic Airway (SALSA), Continuous Positive Airway Pressure (CPAP)
Procedure
Lead sponsor
Sharp HealthCare
Other
Eligibility
33 Weeks to 38 Weeks
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Chula Vista, California • La Mesa, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Phase 1Phase 2 Interventional

Delivery Room CPAP in Extremely Low Birth Weight Infants

NCT01223274
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia, Continuous Positive Airway Pressure
Interventions
CPAP/PEEP, Standard management practices
Device
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 10 Minutes
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
6
States / cities
Birmingham, Alabama • San Diego, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 24, 2026, 3:23 PM EDT
Suspended Phase 2 Interventional

Administration of Surfactant Through an Instillation Device Infasurf® (Calfactant) in Neonates- A Pilot Study

NCT04056741
View directory record Official record
Conditions
RDS of Prematurity, Surfactant Protein B Deficiency, Chronic Lung Disease
Interventions
surfactant airway device
Combination Product
Lead sponsor
ONY
Industry
Eligibility
24 Weeks and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
San Diego, California • St. Petersburg, Florida • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Sep 24, 2026, 3:23 PM EDT
Completed Phase 4 Interventional Results available

Randomized Controlled Trial of Surfactant Delivery Via Laryngeal Mask Airway (LMA) Versus Endotracheal Intubation

NCT01042600
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Endotracheal tube insertion, Laryngeal mask airway insertion
Device
Lead sponsor
Albany Medical College
Other
Eligibility
4 Hours to 48 Hours
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Sep 24, 2026, 3:23 PM EDT